ESPE Abstracts

Background: Novo Nordisk’s long-acting growth hormone (LAGH) is approved by EMA for treating growth hormone deficiency (GHD) in children 3 years and older. The LAGH connected system includes the innovative add-on Mallya connectivity cap (manufactured by BIOCORP, a Novo Nordisk Company), which connects to the pen injector, detects the dose and dose time, and sends data to mobile application via Bluetooth. This marks the first LAGH connected device in Slov...